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Abstract
Background: The G allele of the CD45 77C/G SNP (rs17612648), which has previously been suggested to be
associated with autoimmune disorders, was genotyped in 446 Swedish myasthenia gravis (MG) patients and 2303
matched controls.
Results: There was no association between the polymorphism and patient group as a whole (p = 0.199), nor with
clinical subgroups. Our results add to a growing number of studies unable to find association between the 77C/G
polymorphism and autoimmune disorders. One control sample, from an adult blood donor, was homozygous for
the G allele, yet negative for a panel of auto-antibodies, representing the first homozygous individual studied in
this respect.
Conclusions: The 77C/G mutation does not predispose to MG, and its role in autoimmunity may have to be
re-evaluated.
Background
Myasthenia gravis (MG) is an autoimmune disorder
characterized by the presence of antibodies against the
nicotine acetylcholine receptor on the muscle end-plate,
thereby impairing transmission of nerve impulses to the
muscle. MG occurs in 14/100,000 individuals in Sweden
and patients commonly display thymic abnormalities
such as thymoma and hyperplasia, where the former
usually is associated with a severe disease [1]. Poly-
morphisms in several “classical” autoimmune genes have
previously been shown to be associated with myasthenia
gravis, including IL-1, PTPN22 and TNF-a [2]. Further-
more, an association has also been observed with the
HLA haplotype A1, B8, DR3 [3-5], known to be linked
to several “autoimmune” disorders [6-8].
CD45 (PTPRC), located on chromosome 1q31-32, is a
receptor belonging to the protein tyrosine phosphatase
family, consisting of molecules which have been shown
to be involved in cell growth, differentiation and
signaling. The receptor is heavily expressed on T-cells,
where it comprises up to 10% of all surface proteins [9].
I th a sp r e v i o u s l yb e e ns h o w nt op l a yar o l ei nT - c e l l
receptor signal transduction and activation as well as in
thymic selection of T-cells, both important features in
the development of autoimmunity [9], whereas a lack of
CD45 expression results in severe immunodeficiency
[10,11]. It undergoes complex, cell specific, alternative
splicing to produce eight known isoforms. One isoform,
containing exon 4 (CD45RA+), is expressed mainly by
naïve T-cells, while an isoform with exons 4-6 spliced
o u t( C D 4 5 R O + )i se x p r e s s e db ym o s tm e m o r yT - c e l l s
[ 9 ] .T h eGa l l e l eo fal o wf r e q u e n c ys i n g l en u c l e o t i d e
polymorphism (SNP), 77C/G (rs17612648), has been
reported to disrupt an exonic splicing silencer in exon
4, thereby leading to expression of higher levels of
CD45RA on memory T-cells [12]. This, in turn, alters
the T-cell activation threshold, providing a possible
mechanism for development of autoimmunity [13].
CD45 shares homology and functional features with
PTPN22, another protein member of the tyrosine phos-
phatase family. The latter contains a 1858C/T poly-
morphism (rs2476601) that has been shown to alter the
T-cell activation threshold, due to an intracellular
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morphism has been strongly associated with many auto-
immune disorders, including systemic sclerosis,
rheumatoid arthritis (RA), systemic lupus erythematosus
(SLE), MG, type I diabetes (TID) and multiple sclerosis
(MS) [15-19]. Due to the similar role of CD45 in deter-
mining T-cell activation thresholds, a study investigating
the association between the 77C/G polymorphism and
MS was previously performed [20]. An association in
three of four investigated populations was reported,
thereby triggering a large number of replication studies.
This study was aimed at investigating association of
this polymorphism with myasthenia gravis.
Methods
Patients and controls
Four hundred and sixty-six Swedish Caucasian MG
patients and 2314 ethnically matched controls derived
from anonymized adult blood donors (n = 1594) and
dried blood spot samples from newborns (n = 720) from
a population based study [21] were included in the study.
The diagnosis of myasthenia gravis was made as
described previously [1]. Antibodies against the acetyl-
choline receptor (AChR) were determined by radioim-
munoassay [22], and testing for additional autoantibodies
was performed using Bio Rad Bio-plex ANA and ANCA
screens at the Karolinska University Hospital Laboratory.
Immunoglobulin levels were determined by nephelome-
t r ya tt h eK a r o l i n s k aU n i v e r s i t yH o s p i t a lL a b o r a t o r y .
Clinical information was documented by the primary
physician over the course of treatment, and informed
consent was given at the initial patient visit. Ethical per-
mission was obtained from the Karolinska Institutet for
use of patient and control materials.
CD45 genotyping
Genotyping for the rs17612648 SNP in 466 MG samples
and 2314 controls was performed using matrix-assisted
laser desorption/ionization time-of-flight (MALDI-TOF)
mass spectrometry [23] (SEQUENOM Inc., San Diego,
California, USA) at the Mutation Analysis Facility of the
Karolinska Institutet, Sweden. All samples that were
found to be heterozygous or homozygous for the G
allele were subsequently amplified and subjected to
direct sequencing at Macrogen, South Korea, using the
primers CTGGGAGGAGCATACATTTAGG and
AGCACTAGCATTATCCAAAGAG, in order to verify
the result.
Statistical analysis
The Chi square test was used to compare the allelic fre-
quency of CD45 in patients and controls. For all tests, a
p-value below 0.05 was considered to indicate statistical
significance. Power for the study was calculated using the
“CaTS - Power Calculator for Two Stage Association Stu-
dies” http://www.sph.umich.edu/csg/abecasis/CaTS/ [24].
Patient subgrouping
Due to the complex nature of MG, which may contain
several genetically distinct diseases exhibiting similar
phenotypes, we stratified the patient material into sub-
groups based on the available clinical information.
Patients were thus separated on the basis of sex, anti-
body status (anti-AChR positive or negative), thymic sta-
tus (normal, hyperplasia or thymoma), disease severity
(ocular, generalized or severe) as well as by age of onset.
In the latter case, patients with age of disease onset less
than 40 constituted the early onset group (EOMG),
while those with an age of onset 50 or more were
assigned to the late onset group (LOMG). Anti-AChR
negative patients were defined as those who had never
tested positive for anti-AChR antibodies, and had at
least one negative test on record. We furthermore inves-
tigated possible association with known HLA biases
within MG, specifically within the HLA B8, DR3 haplo-
type (EOMG) and the HLA B7 and DR2 alleles (LOMG)
[25]. For each analysis, a Bonferroni correction was
applied based on the number of independent subgroups
created by the patient stratification.
Results
Of the 466 genotyped MG samples, 20 were removed
due to ambiguous readings, resulting in 446 appropri-
ately typed samples. The number of control samples,
after removing 11 samples with unsuccessful genotyping,
was 2303.
The genotyping results are given in Table 1. Allelic
variants of rs17612648 were not associated with
myasthenia gravis in the patient group as a whole (p =
0.199), although the minor (G) allele appears slightly
more frequently in MG patients than in controls (1.91%
compared with 1.35%). Neither was any subgroup of
MG associated with the SNP (p > 0.260, corrected),
despite a slightly elevated minor allele frequency in
most subgroups. Of all the patient subgroups, only the
LOMG HLA B7 (0.91% MAF) and DR2 (0.81% MAF)
subgroups had a lower frequency of the G allele than
the control population (1.35% MAF), although, due to
the low allele frequency, each group contained only one
heterozygous case.
We furthermore observed a blood donor control sam-
ple homozygous for the G allele, which was confirmed
by sequencing (Figure 1). Due to the presumed deleter-
ious effect of homozygosity of this allele [26], a serum
sample was tested in order to determine if autoantibo-
dies were present. ANA antibodies (Anti-Nucleosome,
Ribosomal P, RNP68, RNP A, Scl-70, Sm, SmRNP, SS-A
(Ro52), SS-A(Ro60), SS-B, Centromere, Jo-1 and
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GBM) could, however, not be demonstrated. Serum
immunoglobulin levels were also normal (IgM = 0.7 g/l,
IgG = 9.7 g/l, IgA = 1.7 g/l). Due to restrictions in the
ethical permission of the study, requesting anonymous
control samples, material for additional analysis, includ-
ing CD45 expression, could not be obtained.
Discussion
The G allele of the CD45 77C/G polymorphism
(rs17612648) was previously reported to be associated
with MS in multiple patient cohorts, sparking interest in
a possible common disease mechanism in related disor-
ders. Table 2 presents an overview of the results of stu-
dies on CD45 77C/G association with autoimmunity to
date. The compiled minor allele (G) frequency from
these studies is approximately 1%; using this figure, our
study has 80% power to detect allelic odds ratios greater
than 2.5, far more sensitive than any study published to
date which has reported significant association of the
polymorphism to autoimmunity (Table 2).
In nine follow up studies on association of the SNP
with MS, only two have reported a significant association
(p =0 . 0 2a n dp = 0.0342) [27,28]. In the latter study, the
G allele was observed in 7 of 176 families and the pedi-
grees of these families were subsequently examined. Sig-
nificance (p = 0.0342) was obtained after the pedigree
disequilibrium test failed to give a significant result, after
which 10,000 bootstrap samples simulated in the soft-
ware TRANSMIT approximated significance tests instead
of a c
2 test. The lack of an accepted statistical approach,
as well as an apparent MAF in cases (1.0-1.5%) similar to
that in the Caucasian population (1-2%) [29], makes the
results questionable. The lack of replication in MS is
notable since the original study found an association in
three out of four independent populations. An early
meta-analysis of the first eight data sets determined that
Table 1 Results of CD45 77C/G genotyping in myasthenia gravis patients and subgroups
MG patients n G C MAF p-val uncorrected p-val corrected OR 95% confidence interval for OR Power (%)
b
All patients 446 17 875 0.019 0.199 - 1.42 0.83-2.45 >99
Female 268 9 527 0.017 0.532 1.000 1.25 0.62-2.53 >99
Male 175 8 342 0.023 0.151 0.302 1.71 0.81-3.61 96
EOMG
a (age of onset ≤40) 208 9 407 0.022 0.176 0.352 1.62 0.80-3.28 98
LOMG
a (age of onset >50) 179 5 353 0.014 0.936 1.000 1.04 0.41-2.60 96
Hyperplasia 161 6 316 0.019 0.442 1.000 1.39 0.60-3.24 93
Thymoma 54 3 105 0.028 0.207 0.621 2.09 0.65-6.78 <70
Normal Thymus 60 2 118 0.017 0.764 1.000 1.24 0.30-5.14 <70
Ocular 42 1 83 0.012 0.902 1.000 0.88 0.12-6.44 <70
Generalized 289 13 565 0.022 0.087 0.260 1.69 0.92-3.09 >99
Severe disease 114 3 225 0.013 0.969 1.000 0.98 0.34-3.14 79
Anti-AChR ab. negative 54 3 105 0.028 0.207 0.414 2.09 0.65-6.78 <70
Anti-AChR ab. positive 389 14 764 0.018 0.321 0.642 1.34 0.75-2.41 >99
HLA B8, DR3 (EOMG) 85 3 167 0.018 0.644 1.000 1.32 0.41-4.24 <70
HLA-B7 (LOMG) 55 1 109 0.009 0.693 1.000 0.67 0.09-4.89 <70
HLA-DR2 (LOMG) 62 1 123 0.008 0.605 1.000 0.60 0.08-4.33 <70
Controls 2303 62 4544 0.013
Allele frequencies for patients and subgroups are given as well as uncorrected and corrected p-values of the 77C/G polymorphism association with the disease. A
Bonferroni correction was applied to subgroups based on the number of independent samples in each.
a EOMG and LOMG patients were anti-AChR antibody positive without the presence of thymoma
b The power of each group/subgroup comparison to detect the minimum allelic OR (4.53) from all studies reporting a significant association of the SNP to a
disorder (Vogel, et. al., 2003, Table 2), at a significance level of 0.05.
Figure 1 Homozygous control sequencing chromatogram.T h e
sequencing trace for the homozygous control sample confirms that
the individual contains the G/G genotype.
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different studies (p = 0.01), and that exclusion of the first
studies of Jacobsen, et. al. would remove heterogeneity
(p = 0.23), resulting in a lack of association (p = 0.50) and
an odds ratio of nearly 1 [30]. Of the 15 data sets from
studies on other autoimmune disorders, only two have
reported positive associations of the SNP to a disorder;
systemic sclerosis (p = 0.029) [31] and autoimmune hepa-
titis (p = 0.015) [32].
Interestingly, homozygosity was observed in one of
our control samples from an adult blood donor. To our
knowledge, this is the first reported individual to be
confirmed to be homozygous for the mutation. Tchilian
et. al. did report a G homozygous anonymous thymus
sample, but the patient was not available for further
testing [33]. Svetko, et. al. also reported four G homozy-
gous individuals (two samples in each of the MS and
control groups), but did not conduct sequencing to con-
firm the finding, nor any additional investigations [34].
The overall MAF measured in the latter study (2.76%)
is, however, higher than the aggregate reported for Cau-
casian samples (1-2%) [29], which indicates a possible
overestimation of the G allele as does the fact that the
genotype counts were not in Hardy Weinberg equili-
brium (p < 0.05). Our control sample was negative for
all tested auto-antibodies, which contradicts the pre-
vious assumption that individuals homozygous for the G
mutation would be prone to autoimmunity.
A recent study investigated levels of CD45RO and
CD45RA cell in German MG patients in which the
Table 2 An overview of published findings investigating association of the 77C/G polymorphism with autoimmune
disorders
Study Year Population Disease Patients
MAF(%) (n)
Controls
MAF(%) (n)
OR 95% confidence
interval for OR
Association
Jacobsen et. al. [20] 2000 Germany MS 3.2 (219) 0.0 (189) NA
† NA
† 1.5 × 10
-4
Jacobsen et. al. [20] 2000 Germany MS 3.2 (108) 0.0 (114) NA
† NA
† 0.0058
Jacobsen et. al. [20] 2000 USA MS 1.6 (122) 1.8 (244) 0.89 0.27-2.91 Not significant
Jacobsen et. al. [20] 2000 Germany MS 3.3 (76) 0.4 (119) 8.06 0.93-69.68 0.0342
Barcellos et. al. [37] 2001 USA MS 1.7 (450) 1.2 (253) 1.41 0.54-3.66 Not significant
Vorechovsky et. al. [38] 2001 Sweden MS 1.5 (630) 1.4 (1044) 1.05 0.59-1.87 Not significant
Vorechovsky et. al. [38] 2001 Sweden CVID 2.3 (44) 1.4 (1044) 1.60 0.38-6.78 Not significant
Vorechovsky et. al. [38] 2001 Sweden IgAD 1.4 (148) 1.4 (1044) 0.94 0.33-2.69 Not significant
Vorechovsky et. al. [38] 2001 UK CVID 1.5 (98) 0.9 (232) 1.79 0.40-8.06 Not significant
Vorechovsky et. al. [38] 2001 UK IgAD 0.0 (17) 0.9 (232) NA
† NA
† Not significant
Miterski et. al. [39] 2002 Germany MS 0.8 (454) 1.4 (347) 0.53 0.20-1.40 Not significant
Wood et. al. [40] 2002 Germany TID 0.2 (228) 1.3 (196) 0.17 0.02-1.46 Not significant
Wood et. al. [40] 2002 Germany Graves 1.3 (297) 1.3 (196) 1.06 0.34-3.25 Not significant
Ballerini et. al.[27] 2002 Italy MS 1.0 (194) 0.0 (222) NA
† NA
† p = 0.02
Gomez-Lira et. al. [30] 2003 Italy MS 1.2 (448) 0.9 (529) 1.30 0.55-3.08 Not significant
Schwinzer et. al. [31] 2003 Germany SSc
a 3.7 (67) 0.7 (205) 5.26 1.24-22.31 p = 0.029
Schwinzer et. al. [31] 2003 Germany SLE 2.0 (98) 0.7 (205) 2.83 0.63-12.75 Not significant
Vogel et. al. [32] 2003 Germany AIH
b 3.2 (190) 0.7 (210) 4.53 1.27-16.19 p = 0.015
Tackenberg et. al. [35] 2003 Germany MG 0.6 (78) 0.0 (303) NA
† NA
† Not significant
Nicholas et. al. [41] 2003 UK MS 2.6 (330) 2.0 (197) 1.28 0.55-2.98 Not significant
Thude et. al. [42] 2004 Germany TID 1.2 (165) 1.1 (220) 1.07 0.28-4.01 Not significant
Cocco et. al.[43] 2004 Sardinia MS 1.0 (246) 0.7 (226) 1.54 0.37-6-47 Not significant
Vyshkina et. al. [28] 2004 USA MS NA (176)
c NA (NA) NA NA p = 0.0342
d
Esteghamat et. al. [44] 2005 Iran AIH
b 0.0 (70) 0.4 (140) NA
† NA
† Not significant
Kirsten et. al. [45] 2008 Germany SSc
a 0.6 (171) 1.4 (179) 0.42 0.08-2.16 Not significant
Pan-Hammarström et. al.[46] 2008 Sweden IgAD 1.3 (232) 1.2 (913) 1.07 0.43-2.66 Not significant
Pan-Hammarström et. al.[46] 2008 Sweden CVID 0.5 (91) 1.2 (913) 0.45 0.06-3.38 Not significant
Szvetko et. al. [34] 2009 Australia MS 3.2 (155) 2.3 (171) 2.25 0.76-6.65 Not significant
† The OR cannot be calculated for genotypes with some allele count of zero.
a Systemic sclerosis
b Autoimmune hepatitis
c Number of families used to study transmission of G allele
d Significance determined using 10,000 bootstrap samples in the software TRANSMIT version 2.5 after pedigree disequilibrium test failed to give a significant
result
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with the disease. However, the number of cases and
controls was too low (n = 78 and n = 303, respectively)
to allow a solid conclusion (80% power to detect allelic
OR greater than 5.6 at a = 0.05) [35]. In that study,
ratios of CD45RO to CD45RA CD8+ T-cells were found
to be significantly lower in patients with late onset MG
(LOMG) as well as in T-cells in patients with thymoma.
These differences suggest an alteration in CD45 expres-
sion independent of the rs17612648 SNP, and provide
evidence that CD45 splicing may be regulated by other
factors. In fact, Zilch et. al. have previously demon-
strated that human/mouse somatic cell hybrids carrying
only the mutant (G) allele are still able to generate
CD45RO [36].
Conclusions
Our results provide strong evidence for a lack of asso-
ciation of the rs17612648 SNP with MG. Furthermore,
the presumed effect of the mutation in autoimmunity is
not as strong as initially suggested, as most studies have
failed to find an association. It is thus likely that the
rs17612648 SNP is not the sole regulator of CD45 iso-
form expression, and that homozygosity for the muta-
tion may result in neither propensity for autoimmunity,
nor an absence of CD45RO expression.
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